Pfizer’s Penicillin Crisis: Delayed Treatment for Pregnant Syphilis Patient

The request was urgent. In late March, a woman in Gila County, Arizona, was diagnosed with syphilis during pregnancy. She required an emergency penicillin injection—ideally 30 days pre-delivery—to prevent life-threatening complications for both mother and child. Without timely treatment, risks included miscarriage, stillbirth, or the newborn suffering from deformities, blindness, or deafness.

The only U.S.-approved treatment for syphilis in pregnancy—Bicillin L-A, a penicillin formulation—was in national shortage since July 2025. Pfizer, the sole supplier, had an emergency protocol for such cases, yet the drug failed to arrive for this patient despite a submitted request.

Public health officials invoked the protocol on March 27, but Pfizer confirmed receipt only on April 1. By April 7, the medication remained unshipped. A coalition leader urged Pfizer to expedite delivery, but by then, the window for prevention had closed. “Mom has delivered, and we missed our chance to prevent congenital syphilis,” an official reported, confirming the medical request form was completed.

This case underscored systemic failures in managing penicillin shortages. In February, health groups had requested Pfizer to reserve doses for emergencies, but the company delayed action. By June, Pfizer cited evaluation processes, highlighting how bureaucratic inertia can imperil critical care. The Arizona incident became a stark reminder of the human cost when supply chain vulnerabilities intersect with public health emergencies.

Source link